Nature Communications (Jan 2018)
Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
- Rahul Nahar,
- Weiwei Zhai,
- Tong Zhang,
- Angela Takano,
- Alexis J. Khng,
- Yin Yeng Lee,
- Xingliang Liu,
- Chong Hee Lim,
- Tina P. T. Koh,
- Zaw Win Aung,
- Tony Kiat Hon Lim,
- Lavanya Veeravalli,
- Ju Yuan,
- Audrey S. M. Teo,
- Cheryl X. Chan,
- Huay Mei Poh,
- Ivan M. L. Chua,
- Audrey Ann Liew,
- Dawn Ping Xi Lau,
- Xue Lin Kwang,
- Chee Keong Toh,
- Wan-Teck Lim,
- Bing Lim,
- Wai Leong Tam,
- Eng-Huat Tan,
- Axel M. Hillmer,
- Daniel S. W. Tan
Affiliations
- Rahul Nahar
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore
- Weiwei Zhai
- Human Genetics, Genome Institute of Singapore
- Tong Zhang
- Human Genetics, Genome Institute of Singapore
- Angela Takano
- Department of Pathology, Singapore General Hospital
- Alexis J. Khng
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore
- Yin Yeng Lee
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore
- Xingliang Liu
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore
- Chong Hee Lim
- Department of Cardiothoracic Surgery, National Heart Centre Singapore
- Tina P. T. Koh
- Department of Cardiothoracic Surgery, National Heart Centre Singapore
- Zaw Win Aung
- Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore
- Tony Kiat Hon Lim
- Department of Pathology, Singapore General Hospital
- Lavanya Veeravalli
- Research Pipeline Development, Genome Institute of Singapore
- Ju Yuan
- Cancer Stem Cell Biology, Genome Institute of Singapore
- Audrey S. M. Teo
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore
- Cheryl X. Chan
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore
- Huay Mei Poh
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore
- Ivan M. L. Chua
- Next Generation Sequencing Platform, Genome Institute of Singapore
- Audrey Ann Liew
- Cancer Stem Cell Biology, Genome Institute of Singapore
- Dawn Ping Xi Lau
- Division of Medical Oncology, National Cancer Centre Singapore
- Xue Lin Kwang
- Division of Medical Oncology, National Cancer Centre Singapore
- Chee Keong Toh
- Division of Medical Oncology, National Cancer Centre Singapore
- Wan-Teck Lim
- Division of Medical Oncology, National Cancer Centre Singapore
- Bing Lim
- Cancer Stem Cell Biology, Genome Institute of Singapore
- Wai Leong Tam
- Cancer Stem Cell Biology, Genome Institute of Singapore
- Eng-Huat Tan
- Division of Medical Oncology, National Cancer Centre Singapore
- Axel M. Hillmer
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore
- Daniel S. W. Tan
- Cancer Stem Cell Biology, Genome Institute of Singapore
- DOI
- https://doi.org/10.1038/s41467-017-02584-z
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 11
Abstract
EGFR mutant lung adenocarcinoma (LUAD) exhibit diverse clinical outcomes in response to targeted therapies. Here the authors show that these LUADs involve a complex genomic landscape with high intratumor heterogeneity, providing insights into the evolutionary trajectory of oncogene-driven LUAD and potential mediators of EGFR TKI resistance.